Primary Tumor Resection Following Favorable Response to Systemic Chemotherapy in Stage IV Pancreatic Adenocarcinoma with Synchronous Metastases: a Bi-institutional Analysis-Reference-Cited by-同舟云学术

Primary Tumor Resection Following Favorable Response to Systemic Chemotherapy in Stage IV Pancreatic Adenocarcinoma with Synchronous Metastases: a Bi-institutional Analysis

Published:2016-09-07 Issue:11 Volume:20 Page:1830-1835
ISSN:1091-255X
Container-title:Journal of Gastrointestinal Surgery
language:en
Short-container-title:J Gastrointest Surg

Author:

Wright G. Paul^ORCID,Poruk Katherine E.,Zenati Mazen S.,Steve Jennifer,Bahary Nathan,Hogg Melissa E.,Zuriekat Amer H.,Wolfgang Christopher L.,Zeh Herbert J.,Weiss Matthew J.

Publisher

Springer Science and Business Media LLC

Subject

Gastroenterology,Surgery

Link

http://link.springer.com/content/pdf/10.1007/s11605-016-3256-2.pdf

Reference17 articles.

1. Howlander N, Noone AM, Krapcho M, Miller D, Bishop K, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). SEER cancer statistics review, 1975-2013, National Cancer Institute. Bethesda, MD. http://seer.cancer.gov/csr/1975_2013/ , based on November 2015 SEER data submission. Accessed May 25, 2016.

2. Conroy T, Desseigne F, Ychou M, Bouché O, Guimbaud R, Bécouarn Y, Adenis A, Raoul JL, Gourgou-Bourgade S, de la Fouchardiere C, Bennouna J, Bachet JB, Kehmissa-Akouz F, Pere-Verge D, Delbaldo C, Assenat E, Chauffert B, Michel P, Montot-Grillot C, Ducreux M for the Groupe Tumeurs Digestives of Unicancer and the PRODIGE Intergroup. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364:1817-1825.

3. Von Hoff DD, Ervin T, Arena F, Chiorean EG, Infante J, Moore M, Seay T, Tjulandin SA, Ma WW, Saleh MN, Harris M, Reni M, Dowden S, Laheru D, Bahary N, Ramanathan RK, Tabernero J, Hidalgo M, Goldstein D, Van Custem E, Wei X, Iglesias J, Renschler MF. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369:1691-1703.

4. Leal JN, Bressan AK, Vachharajani N, Gonen M, Kingham TP, D’Angelica MI, Allen PJ, DeMatteo RP, Doyle MB, Bathe OF, Greig PD, Wei A, Chapman WC, Dixon E, Jarnagin WR. Time-to-surgery and survival outcomes in resectable colorectal liver metastases: a multi-institutional evaluation. J Am Coll Surg. 2016;222:766-779.

5. Tarantino I, Warschkow R, Worni M, Cerny T, Ulrich A, Schmied BM, Guller U. Prognostic relevance of palliative primary tumor removal in 37,793 metastatic colorectal cancer patients: a population-based, propensity score-adjusted trend analysis. Ann Surg. 2015;262:112-120.

Cited by 74 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Conversion surgery for BRCA-mutated pancreatic ductal adenocarcinoma with liver metastasis treated with platinum-based chemotherapy followed by olaparib;Surgical Case Reports;2024-07-30

2. Should liver metastases of pancreatic adenocarcinoma be resected?;Journal of Visceral Surgery;2024-04

3. Faut-il réséquer les métastases hépatiques d’adénocarcinome du pancréas ?;Journal de Chirurgie Viscérale;2024-04

4. Surgery for Oligometastatic Pancreatic Cancer: Defining Biologic Resectability;Annals of Surgical Oncology;2024-03-19

5. Oncological role of surgical resection in patients with pancreatic ductal adenocarcinoma with liver-only synchronous metastases in a single-center retrospective study;Journal of Gastrointestinal Oncology;2023-12